Beyond cancer vaccines: A reason for future optimism with immunomodulatory therapy Review uri icon


MeSH Major

  • Cancer Vaccines
  • Immunomodulation


  • Despite significant scientific knowledge in the field of cancer immunology, therapeutic strategies using cancer vaccines to generate anti-tumor immunity have historically resulted in only modest clinical benefit. Disappointing results from prior cancer vaccine trials are likely due to multifactorial causes. Perhaps the most important is the role of inherent tumor-induced immune suppression and enhanced immunologic tolerance. Current research directed toward understanding the mechanisms of immunologic tolerance has led to the development of promising therapeutic immune regulatory antibodies that inhibit immunologic checkpoints and subsequently enhance immunologic anti-tumor activity. This review discusses the prior challenges associated with cancer vaccines and describes how, by breaking immune inhibition and facilitating immune stimulation, immune regulatory antibodies show great promise in the treatment of a variety of tumors.

publication date

  • September 2011



  • Review



  • eng

PubMed Central ID

  • PMC3189545

Digital Object Identifier (DOI)

  • 10.1097/PPO.0b013e31823261db

PubMed ID

  • 21952288

Additional Document Info

start page

  • 372

end page

  • 8


  • 17


  • 5